Injectable versatile liquid-solid transformation implants alliance checkpoint blockade for magnetothermal dynamic-immunotherapy
Source abstract
Abstract
The ongoing circulating energy loss, low reactive oxygen species (ROS) accumulation and poor immunogenicity of tumors make it difficult to induce sufficient immunogenic cell death (ICD) in the tumor immunosuppressive microenvironment (TIME), resulting in unsatisfactory immunotherapy efficacy. Furthermore, for highly malignant tumors, simply enhancing ICD is insufficient for exhaustively eliminating the tumor and inhibiting metastasis. Herein, we propose a unique magnetothermal-dynamic immunotherapy strategy based on liquid-solid transformation porous versatile implants (Fe3O4/[email protected]) that takes advantage of less energy loss and avoids ongoing circulating losses by minimally invasive injection into tumors. In addition, the magnetothermal effect regresses and eliminates tumors that are not limited by penetration to simultaneously trigger 2,2′-azobis[2-(2-imidazolin-2-yl) propane] dihydrochloride (AIPH) decomposition and generate a large amount of oxygen-irrelevant free radicals and heat shock protein (HSP) accumulation by heating, evoking both intracellular oxidative stress and endoplasmic reticulum (ER) stress to induce large-scale ICD and enhance tumor immunogenicity. More importantly, in orthotopic bilateral breast tumor models, a significant therapeutic effect was obtained after combining amplified ICD with CTLA4 checkpoint blockade. The 21-day primary and distant tumor inhibition rates reached 90%, and the underlying mechanism of the effective synergetic strategy of inducing the T-cell-related response, the immune memory effect and TIME reprogramming in vivo was verified by immune cell analyses. This remarkable therapeutic effect provides a new direction for antitumor immunotherapy based on magnetothermally controlled oxygen-independent free radical release.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Cancer immunotherapy: harnessing the immune system to battle cancer10.1172/JCI83871 ↗
2. Exosome-based immunotherapy: a promising approach for cancer treatment10.1186/s12943-020-01278-3 ↗
3. T cell-mediated immunity to malaria10.1038/s41577-019-0158-z ↗
4. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
5. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy10.15252/emmm.201606674 ↗
6. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials10.1038/d41573-020-00204-y ↗
7. Breast cancer10.1016/S0140-6736(16)31891-8 ↗
8. The landscape of targeted therapies in TNBC10.3390/cancers12040916 ↗
9. Immunogenic cell death in cancer therapy10.1146/annurev-immunol-032712-100008 ↗
10. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency
11. Emerging photodynamic nanotherapeutics for inducing immunogenic cell death and potentiating cancer immunotherapy10.1016/j.biomaterials.2022.121433 ↗
12. Enhanced ferroptosis by oxygen-boosted phototherapy based on a 2-in-1 nanoplatform of ferrous hemoglobin for tumor synergistic therapy10.1021/acsnano.9b09426 ↗
13. A photosensitizer discretely loaded nanoaggregate with robust photodynamic effect for local treatment triggers systemic antitumor responses10.1021/acsnano.1c10590 ↗
14. A versatile gas-generator promoting drug release and oxygen replenishment for amplifying photodynamic-chemotherapy synergetic anti-tumor effects10.1016/j.biomaterials.2021.120985 ↗
15. Recent progress of alkyl radicals generation-based agents for biomedical applications10.1002/adhm.202100055 ↗
16. Alkyl carbon-carbon bond formation by nickel/photoredox cross-coupling10.1002/anie.201809431 ↗
17. Supramolecular photosensitizers rejuvenate photodynamic therapy10.1039/C7CS00594F ↗
18. Mitochondrial glutathione depletion nanoshuttles for oxygen-irrelevant free radicals generation: a cascaded hierarchical targeting and theranostic strategy against hypoxic tumor10.1021/acsami.1c24708 ↗
19. Magnetic nanoparticles and clusters for magnetic hyperthermia: optimizing their heat performance and developing combinatorial therapies to tackle cancer10.1039/D1CS00427A ↗
20. Recent advances in hyperthermia therapy-based synergistic immunotherapy10.1002/adma.202004788 ↗
21. Mild magnetic hyperthermia-activated innate immunity for liver cancer therapy10.1021/jacs.1c02537 ↗
22. Linking cellular stress responses to systemic homeostasis10.1038/s41580-018-0068-0 ↗
23. Synthesis and optimization of MoS(2)@Fe(3)O(4)-ICG/Pt(IV) nanoflowers for MR/IR/PA bioimaging and combined PTT/PDT/chemotherapy triggered by 808 nm laser
24. Clinically established biodegradable long acting injectables: an industry perspective10.1016/j.addr.2020.11.008 ↗
25. Diverse applications of nanomedicine10.1021/acsnano.6b06040 ↗
26. Immunogenic and tolerogenic cell death10.1038/nri2545 ↗
27. Oxidative stress in cancer10.1016/j.ccell.2020.06.001 ↗
28. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer10.1039/C8CS00618K ↗
29. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade10.1016/j.cell.2021.09.020 ↗
30. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities10.1038/s41573-022-00493-5 ↗
31. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer10.1038/nature14292 ↗
32. A three-in-one strategy: injectable biomimetic porous hydrogels for accelerating bone regeneration via shape-adaptable Scaffolds, controllable magnesium ion release, and enhanced osteogenic differentiation10.1021/acs.biomac.1c00842 ↗
33. Reactive oxygen species-responsive and Raman-traceable hydrogel combining photodynamic and immune therapy for postsurgical cancer treatment10.1038/s41467-022-32160-z ↗
34. Responsive hydrogels based on triggered click reactions for liver cancer
35. Endoplasmic reticulum stress: an arising target for metal-based anticancer agents10.1039/D0CS00259C ↗
36. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer10.1016/j.cell.2016.12.004 ↗
37. ER stress-induced inflammation: does it aid or impede disease progression?10.1016/j.molmed.2012.06.010 ↗
38. Dying cells actively regulate adaptive immune responses10.1038/nri.2017.9 ↗
39. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
40. DAMP-sensing receptors in sterile inflammation and inflammatory diseases10.1038/s41577-019-0215-7 ↗
41. Dendritic cell subsets in T cell programming: location dictates function10.1038/s41577-018-0088-1 ↗
42. Dendritic cell regulation of T helper cells10.1146/annurev-immunol-101819-025146 ↗
43. The foundations of immune checkpoint blockade and the ipilimumab approval decennial10.1038/s41573-021-00345-8 ↗
44. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review10.1001/jamaoncol.2016.1051 ↗
45. Regulatory circuits of T cell function in cancer10.1038/nri.2016.80 ↗
46. Metabolic regulation of T cell longevity and function in tumor immunotherapy10.1016/j.cmet.2017.06.016 ↗
47. In vivo CD4(+) T cell differentiation and function: revisiting the Th1/Th2 paradigm10.1146/annurev-immunol-103019-085803 ↗
48. Tissue-resident memory T cells in breast cancer control and immunotherapy responses10.1038/s41571-020-0333-y ↗